EVI is pleased to announce a symposium on global health issues under the Patronage of the Minister for Science, Research and Art, Baden Württemberg, that will take place in Heidelberg, 26 February 2013 on the occasion of EVI´s 15th Anniversary. The agenda is available.
The Malaria Vectored Vaccine Consortium (MVVC) is funded by the European and Developing Countries' Clinical Trials Partnership (EDCTP), which is developing much needed malaria vaccines.
The overall aim of this short course is to provide an understanding of the methods used in the evaluation of vaccines, from early human trials through to assessment of population impact and policy.
1. MVVC 2 (Malaria Vectored Vaccines Consortium 2): Field Trials of a New Combination Malaria Vaccine in West African Adults and Children
2. P27A CTb (P27A Phase Ib Clinical Trial)
Please open news item for details
The European Vaccine Initiative urges continued and sustainable malaria vaccine development efforts and funding.
TRANSVAC is now launching the second Training course "Practical approaches to vaccine development".
In addition to the initial groups, TRANSVAC transnational access platform has integrated five additional groups, who provide their services to users on a free and paid basis. Read the TRANSVAC Press release about the new services.
The first TRANSVAC training course on “Practical approaches to vaccine development” was held on 3-6 September 2012 at the Vaccine Formulation Laboratory (VFL) training center, University of Lausanne, Switzerland. Read the Post-training advert to learn more about the course agenda and the feedbacks from the participants.
EVI extends thanks to all speakers, chairs and other participants for making the 2012 RdV a resounding success.
Please visit the Rendez-Vous page for:
Meeting report, agenda, list of participants and photos
Held in Brussels on the 13th June 2012 , the Second TRANSVAC Stakeholder Workshop focused on two main topics:
I) What are regulatory challenges in vaccine development and how can we solve them together?
II) How can the 'One Health' concept help us during the quest for new and better vaccines?